[go: up one dir, main page]

SV1997000018A - Proteinas inhibisoras (bikunin humano) - Google Patents

Proteinas inhibisoras (bikunin humano)

Info

Publication number
SV1997000018A
SV1997000018A SV1997000018A SV1997000018A SV1997000018A SV 1997000018 A SV1997000018 A SV 1997000018A SV 1997000018 A SV1997000018 A SV 1997000018A SV 1997000018 A SV1997000018 A SV 1997000018A SV 1997000018 A SV1997000018 A SV 1997000018A
Authority
SV
El Salvador
Prior art keywords
inhibitor proteins
human bikunin
proteins
bikunin
human
Prior art date
Application number
SV1997000018A
Other languages
English (en)
Inventor
Paul P Tamburini
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of SV1997000018A publication Critical patent/SV1997000018A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A PROTEINAS, POLIPEPTIDOS, SECUENCIAS DE ACIDO NUCLEICO, CONTRUCCIONES, VECTORES DE EXPRESION, CELULAS HUESPED, COMPOSICIONES FARMACEUTICAS DE BICUNINA PLACENTARIA HUMANA, DOMINIOS DE INHIBICION DE LA SERINA PROTEASA Y FRAGMENTOS DE LOS MISMOS, Y METODOS PARA USARLOS.
SV1997000018A 1996-03-11 1997-03-11 Proteinas inhibisoras (bikunin humano) SV1997000018A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1310696P 1996-03-11 1996-03-11
US1979396P 1996-06-14 1996-06-14
US72525196A 1996-10-04 1996-10-04

Publications (1)

Publication Number Publication Date
SV1997000018A true SV1997000018A (es) 1999-01-14

Family

ID=27359773

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1997000018A SV1997000018A (es) 1996-03-11 1997-03-11 Proteinas inhibisoras (bikunin humano)

Country Status (27)

Country Link
US (3) US6583108B1 (es)
EP (1) EP0891426B1 (es)
JP (2) JP3469584B2 (es)
KR (1) KR100356956B1 (es)
AR (3) AR006188A1 (es)
AT (1) ATE328083T1 (es)
AU (1) AU716923B2 (es)
BR (1) BR9708021A (es)
CA (1) CA2247888A1 (es)
CO (1) CO4600683A1 (es)
DE (1) DE69735996T2 (es)
DK (1) DK0891426T3 (es)
ES (1) ES2263174T3 (es)
HR (1) HRP970144B1 (es)
HU (1) HU226419B1 (es)
ID (1) ID16224A (es)
IL (1) IL126115A (es)
IN (1) IN192874B (es)
MY (1) MY120693A (es)
NZ (1) NZ331540A (es)
PA (1) PA8426301A1 (es)
PL (1) PL188387B1 (es)
PT (1) PT891426E (es)
SV (1) SV1997000018A (es)
TR (1) TR199801794T2 (es)
WO (1) WO1997033996A2 (es)
YU (1) YU8997A (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
DK0891426T3 (da) 1996-03-11 2006-10-02 Bayer Corp Humant bikunin
US6262233B1 (en) * 1997-01-31 2001-07-17 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
JP3819239B2 (ja) * 1998-12-22 2006-09-06 バイエル アクチェンゲゼルシャフト 粘膜線毛クリアランスの速度を促進する方法
US7704958B1 (en) 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
IL140993A0 (en) 2000-05-15 2002-02-10 Bayer Ag Trypsin substrate and diagnostic device, and method of using same
IL140994A (en) * 2000-05-15 2005-12-18 Bayer Ag Urinary trypsin inhibitor assay containing a chelating agent
US6955921B2 (en) * 2001-04-30 2005-10-18 Bayer Corporation Trypsin substrate and diagnostic device, and method of using same
CA2460653A1 (en) * 2001-11-05 2003-05-15 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE528014T1 (de) 2002-06-07 2011-10-15 Dyax Corp Polypeptid mit modifizierten kunitz domains
JP4903036B2 (ja) 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
DE602004025380D1 (de) * 2003-10-10 2010-03-18 Multicell Technologies Inc Immortalisierte hepatozyten
US7419665B2 (en) * 2003-10-16 2008-09-02 Siemens Healthcare Diagnostics Inc. Monoclonal antibodies for detection of urinary trypsin inhibitors
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
WO2005119524A2 (en) 2004-06-04 2005-12-15 Therasense, Inc. Diabetes care host-client architecture and data management system
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
BRPI0520032A2 (pt) 2005-02-18 2009-04-14 Angiochem Inc moléculas para transportar um composto através da barreira hematoencefálica
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
WO2007009229A1 (en) 2005-07-15 2007-01-25 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
LT1981519T (lt) * 2005-12-29 2018-04-25 Dyax Corp. Proteazės slopinimas
AU2007299562A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor
WO2008058167A2 (en) * 2006-11-07 2008-05-15 Case Western Reserve University Method for treating disorders associated with complement activation
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2170932A4 (en) * 2007-06-20 2012-10-10 Phylogica Ltd COMPOSITIONS AND APPLICATIONS THEREOF IN THE TREATMENT OF ACUTE ATOMIC SYNDROME (ARDS) AND ASSOCIATED CLINICAL ILLNESSES
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
WO2009127072A1 (en) * 2008-04-18 2009-10-22 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2740317A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US9938353B2 (en) 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US10478508B2 (en) 2012-01-10 2019-11-19 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
LT3110434T (lt) 2014-02-24 2018-12-27 Takeda Gmbh Sulieti uti baltymai
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CN116077648A (zh) 2015-12-11 2023-05-09 武田药品工业株式会社 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
EP4114428A4 (en) 2020-03-05 2025-03-12 Diamedica USA Inc. ULINASTATIN POLYPEPTIDES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE59007737D1 (de) * 1989-05-13 1995-01-05 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel.
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
EP0439442B1 (en) 1990-01-25 1996-03-06 Washington University Factor x-laci hybrid protein
EP1325931B1 (en) 1991-03-01 2009-05-13 Dyax Corporation Inhibitors of human neutrophil elastase
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
WO1994001461A1 (en) 1992-07-13 1994-01-20 Corvas International, Inc. BOVINE PANCREATIC TRYPSIN INHIBITOR DERIVED INHIBITORS OF FACTOR Xa
WO1994012637A2 (en) 1992-12-02 1994-06-09 Zymogenetics, Inc. Novel human amyloid protein precursor homologue and kunitz-type inhibitors
US5436153A (en) 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
EP0739355B1 (en) 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
ES2229236T3 (es) 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
WO1996003503A1 (en) 1994-07-21 1996-02-08 The Green Cross Corporation Process for producing urinary trypsin inhibitor and domains thereof, novel polypeptide related to the both, and process for producing the polypeptide
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
AU5854096A (en) 1995-05-08 1996-11-29 Scios Inc. Kunitz type protease inhibitors
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
DK0891426T3 (da) 1996-03-11 2006-10-02 Bayer Corp Humant bikunin
US6262233B1 (en) 1997-01-31 2001-07-17 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity

Also Published As

Publication number Publication date
JP2004000208A (ja) 2004-01-08
AR053063A2 (es) 2007-04-18
HRP970144A2 (en) 1998-04-30
WO1997033996A2 (en) 1997-09-18
WO1997033996A3 (en) 1997-11-13
PL328822A1 (en) 1999-02-15
HUP9902698A2 (hu) 1999-11-29
TR199801794T2 (xx) 2000-07-21
MY120693A (en) 2005-11-30
DK0891426T3 (da) 2006-10-02
AR058982A1 (es) 2008-03-05
AR006188A1 (es) 1999-08-11
US20060172946A1 (en) 2006-08-03
PL188387B1 (pl) 2005-01-31
EP0891426B1 (en) 2006-05-31
EP0891426A2 (en) 1999-01-20
IL126115A0 (en) 1999-05-09
HRP970144B1 (en) 2004-10-31
AU716923B2 (en) 2000-03-09
IL126115A (en) 2007-03-08
CO4600683A1 (es) 1998-05-08
US6583108B1 (en) 2003-06-24
JP3469584B2 (ja) 2003-11-25
DE69735996T2 (de) 2007-02-15
PA8426301A1 (es) 2000-05-24
US7019123B2 (en) 2006-03-28
ES2263174T3 (es) 2006-12-01
KR19990087697A (ko) 1999-12-27
ATE328083T1 (de) 2006-06-15
YU8997A (sh) 1999-09-27
DE69735996D1 (de) 2006-07-06
HU226419B1 (en) 2008-12-29
PT891426E (pt) 2006-10-31
CA2247888A1 (en) 1997-09-18
US20030194398A1 (en) 2003-10-16
US7452859B2 (en) 2008-11-18
BR9708021A (pt) 1999-07-27
NZ331540A (en) 1999-10-28
ID16224A (id) 1997-09-11
AU2207797A (en) 1997-10-01
HUP9902698A3 (en) 2001-06-28
IN192874B (es) 2004-05-29
KR100356956B1 (ko) 2003-03-15
JP2001521367A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
SV1997000018A (es) Proteinas inhibisoras (bikunin humano)
DK0929564T3 (da) Höjniveau-ekspression af proteiner
PT873405E (pt) Elementos de sequencia que aumentam a expressao (ease) para sistemas de expressao eucarioticos
DK0851868T3 (da) Höjniveau-ekspression af proteiner
TR199501134A2 (tr) Memeli ve viral proteinleri asiri ifade edilmesi.
ES2149149T1 (es) Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion.
MX9302917A (es) Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene.
AR009436A1 (es) UNA PROTEíNA DE FUSIoN FC-OB, UNA SECUENCIA DE ÁCIDO NUCLEICO QUE LA CODIFICA, UN VECTOR, PROCEDIMIENTO DE PREPARACIoN, COMPOSICIONES FARMACÉUTICAS Y USOS.
DK161015C (da) Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop
DE60144145D1 (de) Subtilisin-variante
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
CY1108175T1 (el) ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR
ATE384787T1 (de) Tripeptidyl-aminopeptidase
FI970979A0 (fi) Muokatut ihmisen C3-proteiinit
AR025969A1 (es) Homologos de ifn-alfa
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
FI896242A7 (fi) HIV-ENV-proteiineihin liittyviä synteettisiä peptidejä
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
ES2045004T3 (es) Procedimiento para la preparacion de proteinas extra\as en estreptomicetos.
DE3685636D1 (de) Lysozymbetreffende peptide.
CO5070672A1 (es) Polipeptido de proteina c humana
ATE427355T1 (de) Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna
ECSP972054A (es) Bicunina humana

Legal Events

Date Code Title Description
FD Lapse